Allena Pharmaceuticals Inc (ALNA) Receives Consensus Rating of “Buy” from Brokerages

Allena Pharmaceuticals Inc (NASDAQ:ALNA) has received a consensus rating of “Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $29.57.

ALNA has been the subject of several research reports. Zacks Investment Research cut Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 9th. Wedbush reissued a “buy” rating and issued a $38.00 price objective on shares of Allena Pharmaceuticals in a research report on Tuesday, October 23rd. Jefferies Financial Group initiated coverage on Allena Pharmaceuticals in a research report on Thursday, November 8th. They issued a “buy” rating and a $22.00 price objective for the company. ValuEngine raised Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, December 12th. Finally, B. Riley reissued a “buy” rating and issued a $22.00 price objective on shares of Allena Pharmaceuticals in a research report on Friday, December 21st.

Shares of ALNA stock opened at $7.53 on Wednesday. Allena Pharmaceuticals has a 12 month low of $4.80 and a 12 month high of $17.56. The company has a debt-to-equity ratio of 0.17, a quick ratio of 14.75 and a current ratio of 14.75. The company has a market cap of $156.32 million, a price-to-earnings ratio of -1.57 and a beta of 1.31.

Allena Pharmaceuticals (NASDAQ:ALNA) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.01. On average, sell-side analysts anticipate that Allena Pharmaceuticals will post -1.76 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. Morgan Stanley lifted its position in Allena Pharmaceuticals by 126.0% in the third quarter. Morgan Stanley now owns 1,856,640 shares of the company’s stock worth $19,941,000 after purchasing an additional 1,034,990 shares during the period. Partner Fund Management L.P. lifted its position in Allena Pharmaceuticals by 1.7% in the third quarter. Partner Fund Management L.P. now owns 1,768,568 shares of the company’s stock worth $18,994,000 after purchasing an additional 28,763 shares during the period. BlackRock Inc. lifted its position in Allena Pharmaceuticals by 1.7% in the third quarter. BlackRock Inc. now owns 577,443 shares of the company’s stock worth $6,201,000 after purchasing an additional 9,736 shares during the period. Vanguard Group Inc lifted its position in Allena Pharmaceuticals by 2.2% in the third quarter. Vanguard Group Inc now owns 349,819 shares of the company’s stock worth $3,757,000 after purchasing an additional 7,400 shares during the period. Finally, Vanguard Group Inc. lifted its position in Allena Pharmaceuticals by 2.2% in the third quarter. Vanguard Group Inc. now owns 349,819 shares of the company’s stock worth $3,757,000 after purchasing an additional 7,400 shares during the period. 84.40% of the stock is owned by hedge funds and other institutional investors.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

See Also: Stock Selection – What is cash flow?

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply